# EDGAR Filing Document

**Accession Number:** 0001610853
**File Stem:** 0001104659-25-066994
**Filing Date:** 2025-7
**Character Count:** 35387
**Document Hash:** db4b43c8ec200b4ca62723b47e66d9ab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-066994.hdr.sgml**: 20250710

**ACCESSION NUMBER**: 0001104659-25-066994

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 6

**FILED AS OF DATE**: 20250710

**DATE AS OF CHANGE**: 20250710

**EFFECTIVENESS DATE**: 20250710

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HELIUS MEDICAL TECHNOLOGIES, INC.
- **CENTRAL INDEX KEY:** 0001610853
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 364787690
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-288608
- **FILM NUMBER:** 251116501

**BUSINESS ADDRESS:**
- **STREET 1:** 642 NEWTOWN YARDLEY ROAD
- **CITY:** NEWTOWN
- **STATE:** PA
- **ZIP:** 18940
- **BUSINESS PHONE:** 215-944-6100

**MAIL ADDRESS:**
- **STREET 1:** 642 NEWTOWN YARDLEY ROAD
- **CITY:** NEWTOWN
- **STATE:** PA
- **ZIP:** 18940

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HELIUS MEDICAL TECHNOLOGIES, INC
- **DATE OF NAME CHANGE:** 20180517

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HELIUS MEDICAL TECHNOLOGIES, INC.
- **DATE OF NAME CHANGE:** 20140613

**As filed with the Securities and Exchange Commission on July 10, 2025**

**Registration No. 333-**

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549**

**FORM S-8<br> REGISTRATION STATEMENT<br> *UNDER<br> THE SECURITIES ACT OF 1933***

------

**H** **ELIUS MEDICAL TECHNOLOGIES, INC.<br> (Exact name of registrant as specified in its charter)**

------

---

| | |
|:---|:---|
| **Delaware** | **36-4787690** |
| **(State or other jurisdiction of<br> incorporation or organization)** | **(I.R.S. Employer<br> Identification No.)** |
| **642 Newtown Yardley Road, Suite 100<br> Newtown, Pennsylvania** | **18940** |
| **(Address of principal executive offices)** | **(Zip code)** |

---

**Helius Medical Technologies, Inc. 2022 Equity Incentive Plan**

**(Full title of the plan)**

**Dane C. Andreeff<br> President and Chief Executive Officer<br> Helius Medical Technologies, Inc.<br> 642 Newtown Yardley Road, Suite 100<br> Newtown, Pennsylvania 18940<br> (215) 944-6100<br> (Name, address, and telephone number, including area code, of agent for service)**

------

***Copy to:***

**Phillip D. Torrence, Esq.<br> Jeffrey Kuras, Esq.<br> Honigman LLP<br> 650 Trade Center Way, Suite 200<br> Kalamazoo, Michigan 49002-0402<br> (269) 337-7700**

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ◻ | Accelerated filer | ◻ |
| Non-accelerated filer | ⌧ | Smaller reporting company | ⌧ |
|  |  | Emerging growth company | ◻ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**EXPLANATORY NOTE**

**2022 Equity Incentive Plan**

This Registration Statement on Form S-8 is being filed by Helius Medical Technologies, Inc. (the ***"Company,"*** the ***"Registrant***,***" "we***,***" "us***,***"*** or ***"our"***), for the purpose of registering an additional 240,000 shares of Class A common stock, par value $0.001 per share (the ***"Common Stock"***), that may be issued pursuant to Awards (as defined in the 2022 Equity Incentive Plan) under the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan, as amended (the "***2022 Equity Incentive Plan***").

Pursuant to General Instruction E to Form S-8, this Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements of the Company on Form S-8 relating to the 2022 Equity Incentive Plan, respectively, are effective, and the Company's Registration Statements on Form S-8 previously filed with the Securities and Exchange Commission (the "***Commission***") on [May 31, 2022 (File No. 333-265324)](https://www.sec.gov/Archives/edgar/data/1610853/000114036122021320/brhc10038242_s8.htm), [January 19, 2023 (File No. <u>333-269305</u>)](https://www.sec.gov/Archives/edgar/data/1610853/000110465923005074/tm233288d1_s8.htm), [July 24, 2024 (File No. <u>333-280978</u>)](https://www.sec.gov/Archives/edgar/data/1610853/000110465924082337/tm2420001d1_s8.htm) and [March 25, 2025 (File No. <u>333-286100</u>)](https://www.sec.gov/Archives/edgar/data/1610853/000110465925027809/tm259936d1_s8.htm) registering shares of Common Stock issuable under the 2022 Equity Incentive Plan are incorporated by reference and made part of this Registration Statement, except as amended hereby.

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The information specified in Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the ***"Securities Act"***) and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3.** **Incorporation of Documents by Reference**.

The following documents filed with the Securities and Exchange Commission (the "***Commission***") by the Registrant are hereby incorporated by reference in this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;a) [the Registrant's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Commission on <u>March 25, 2025</u>;](https://www.sec.gov/ix?doc=/Archives/edgar/data/1610853/000155837025003619/hsdt-20241231x10k.htm)

&nbsp;&nbsp;&nbsp;&nbsp;b) [the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the Commission on <u>May 1, 2025</u>;](https://www.sec.gov/ix?doc=/Archives/edgar/data/1610853/000155837025006120/hsdt-20250331x10q.htm)

&nbsp;&nbsp;&nbsp;&nbsp;c) the
 Registrant's Current Reports on Form 8-K filed with the Commission on [January 15, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1610853/000110465925003623/tm253406d1_8k.htm) , <u>[January 24, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1610853/000155837025000407/hsdt-20250121x8k.htm)</u>, <u>[February 7, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1610853/000155837025000717/hsdt-20250207x8k.htm)</u>, <u>[April 4, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1610853/000155837025004488/hsdt-20250331x8k.htm)</u>, <u>[April 22, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1610853/000155837025005150/hsdt-20250421x8k.htm)</u>, <u>[April 25, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1610853/000155837025005510/hsdt-20250424x8k.htm)</u>, <u>[April 30, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1610853/000155837025005939/hsdt-20250430x8k.htm)</u>, <u>[May 23, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1610853/000155837025008132/hsdt-20250523x8k.htm)</u>, <u>[June 4, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1610853/000110465925056246/tm2516542d1_8k.htm)</u>, <u>[June 20, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1610853/000155837025008779/hsdt-20250616x8k.htm)</u>, <u>[June 23, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1610853/000155837025008785/hsdt-20250623x8k.htm)</u>, <u>[June 27, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1610853/000155837025008942/hsdt-20250627x8k.htm)</u>, <u>[July 7, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1610853/000110465925066161/tm2519791d2_8k.htm)</u> and <u>[July 9, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1610853/000155837025009138/hsdt-20250707x8k.htm)</u> and

&nbsp;&nbsp;&nbsp;&nbsp;d) the
 description of the Registrant's Common Stock contained in the Registrant's <u>[Form 8-A (File No. 001-38445) filed with the Commission on April 4, 2018](https://www.sec.gov/Archives/edgar/data/1610853/000119312518106706/d560270d8a12b.htm)</u>, as amended
 by the description of the Common Stock contained in <u>[Exhibit 4.7](https://www.sec.gov/Archives/edgar/data/1610853/000156459021012121/hsdt-ex47_10.htm)</u> to the Registrant's
 Annual Report on Form 10-K for the year ended December 31, 2020, and as further
 amended by any subsequent amendment or report filed for the purpose of updating such description.

In addition, all documents the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the ***"Exchange Act"***), after the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities covered hereby then remaining unsold are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents. Notwithstanding anything herein, the Registrant is not incorporating by reference any information furnished under Item 2.02 or Item 7.01 of any Current Report on Form 8-K, unless, and to the extent, specified in any such Current Report on Form 8-K.

Any statement herein or contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any subsequently filed document, which also is or is deemed to be incorporated by reference herein, modifies or supersedes such prior statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.

**Item 4.** **Description of Securities**.

Not applicable.

**Item 5.** I**nterests of Named Experts and Counsel.**

Not applicable.

**Item 6.** **Indemnification of Directors and Officers**.

We are incorporated under the laws of the State of Delaware. Section 102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director or officer, except where the director or officer breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit.

Section 145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys' fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines upon application that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

As permitted by the Delaware General Corporation Law, our amended and restated bylaws provide that: (1) we are required to indemnify our directors and executive officers to the fullest extent permitted by the Delaware General Corporation Law; (2) we may, in our discretion, indemnify our other officers, employees and agents as set forth in the Delaware General Corporation Law; (3) we are required, upon satisfaction of certain conditions, to advance all expenses incurred by our directors and executive officers in connection with certain legal proceedings; (4) the rights conferred in the bylaws are not exclusive; (5) we are authorized to enter into indemnification agreements with our directors, officers, employees and agents; and (6) we may secure insurance on behalf of any director, officer, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of Delaware law.

*Indemnification Agreements*

We have entered into indemnification agreements with our directors and officers. These agreements provide broader indemnity rights than those provided under the Delaware General Corporation Law and the Registrant's certificate of incorporation, as amended. The indemnification agreements are not intended to deny or otherwise limit third-party or derivative suits against us or our directors or officers, but to the extent a director or officer were entitled to indemnity or contribution under the indemnification agreement, the financial burden of a third-party suit would be borne by us, and we would not benefit from derivative recoveries against the director or officer. Such recoveries would accrue to our benefit but would be offset by our obligations to the director or officer under the indemnification agreement.

*Insurance Policy*

We maintain a directors' and officers' liability insurance policy. The policy insures directors and officers against unindemnified losses arising from certain wrongful acts in their capacities as directors and officers and reimburses us for those losses for which we have lawfully indemnified the directors and officers. The policy contains various exclusions.

The foregoing summaries are not intended to be exhaustive and are qualified in their entirety by reference to the complete text of the statute, the Registrant's certificate of incorporation, as amended and the agreements referred to above and are qualified in their entirety by reference thereto.

**Item 7.** **Exemption from Registration Claimed**.

Not applicable.

**Item 8.** **Exhibits**.

**EXHIBIT INDEX**

The following exhibits are filed as part of this registration statement.

**INDEX TO EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description** |
| [4.1](https://www.sec.gov/Archives/edgar/data/1610853/000156459018020736/hsdt-ex31_66.htm) | [Certificate of Conversion filed with the Delaware Secretary of State on July 18, 2018 (incorporated by reference to Exhibit 3.1 to the Form 10-Q filed August 9, 2018)](https://www.sec.gov/Archives/edgar/data/1610853/000156459018020736/hsdt-ex31_66.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1610853/000119312518312155/d646047dex31.htm) | [Certificate of Incorporation, as corrected (incorporated by reference to Exhibit 3.1 to the Form 8-K filed October 30, 2018)](https://www.sec.gov/Archives/edgar/data/1610853/000119312518312155/d646047dex31.htm) |
| [4.3](https://www.sec.gov/Archives/edgar/data/1610853/000156459020058917/hsdt-ex31_7.htm) | [Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on December 31, 2020)](https://www.sec.gov/Archives/edgar/data/1610853/000156459020058917/hsdt-ex31_7.htm) |
| [4.4](https://www.sec.gov/Archives/edgar/data/1610853/000110465923036609/tm2310398d1_ex3-1.htm) | [Certificate of Designation of the Series B Preferred Stock of the Registrant (incorporated by reference to Exhibit 3.1(a) to the Registration Statement on Form 8-A, filed March 24, 2023)](https://www.sec.gov/Archives/edgar/data/1610853/000110465923036609/tm2310398d1_ex3-1.htm) |
| [4.5](https://www.sec.gov/Archives/edgar/data/1610853/000110465923092276/tm2323789d1_ex3-1.htm) | [Corrected Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Form 8-K filed August 16, 2023)](https://www.sec.gov/Archives/edgar/data/1610853/000110465923092276/tm2323789d1_ex3-1.htm) |
| [4.6](https://www.sec.gov/Archives/edgar/data/1610853/000155837025005939/hsdt-20250430xex3d1.htm) | [Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Form 8-K filed April 30, 2025)](https://www.sec.gov/Archives/edgar/data/1610853/000155837025005939/hsdt-20250430xex3d1.htm) |
| [<u>4.7</u>](https://www.sec.gov/Archives/edgar/data/1610853/000155837024003414/hsdt-20240312xex3d1.htm) | [Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Form 8-K filed March 15, 2024)](https://www.sec.gov/Archives/edgar/data/1610853/000155837024003414/hsdt-20240312xex3d1.htm) |
| [4.8](https://www.sec.gov/Archives/edgar/data/1610853/000156459022005702/hsdt-ex101_8.htm) | [Helius Medical Technologies, Inc. 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form 8-K filed February 18, 2022)](https://www.sec.gov/Archives/edgar/data/1610853/000156459022005702/hsdt-ex101_8.htm) |
| [4.9](https://www.sec.gov/Archives/edgar/data/1610853/000156459022005702/hsdt-ex103_9.htm) | [Helius Medical Technologies, Inc. 2022 Equity Incentive Plan Form of Stock Option Agreement (incorporated by reference to Exhibit 10.3 to the Form 8-K filed February 18, 2022)](https://www.sec.gov/Archives/edgar/data/1610853/000156459022005702/hsdt-ex103_9.htm) |
| [4.10](https://www.sec.gov/Archives/edgar/data/1610853/000155837024009613/hsdt-20240627xex10d1.htm) | [Amendment to the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form 8-K filed June 28, 2024)](https://www.sec.gov/Archives/edgar/data/1610853/000155837024009613/hsdt-20240627xex10d1.htm) |
| [4.11\*](tm2520226d1_ex4-11.htm) | [Second Amendment to the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan](tm2520226d1_ex4-11.htm) |
| [5.1\*](tm2520226d1_ex5-1.htm) | [Opinion of Honigman LLP](tm2520226d1_ex5-1.htm) |
| [23.1\*](tm2520226d1_ex23-1.htm) | [Consent of Baker Tilly US, LLP](tm2520226d1_ex23-1.htm) |
| [23.2\*](tm2520226d1_ex5-1.htm) | [Consent of Honigman LLP (included in its opinion filed as Exhibit 5.1 to this Registration Statement)](tm2520226d1_ex5-1.htm) |
| [24.1\*](#a_001) | [Power of Attorney (included after the signature of the Registrant contained on Signature Page of this Registration Statement)](#a_001) |
| [107\*](tm2520226d1_ex-filingfees.htm) | [Filing Fee Table](tm2520226d1_ex-filingfees.htm) |

---

\*Filed herewith.

**Item 9.** **Undertakings.**

(a) The Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Filing Fee Tables" or "Calculation of Registration Fee" table, as applicable, in the effective Registration Statement;

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

*provided, however,* that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Registration Statement; and

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant's annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, hereunto duly authorized, in the City of Newtown, State of Pennsylvania, on July 10, 2025.

---

| | | |
|:---|:---|:---|
| Helius Medical Technologies, Inc. | Helius Medical Technologies, Inc. | Helius Medical Technologies, Inc. |
| By: | /s/ Dane C. Andreeff | /s/ Dane C. Andreeff |
|  | Name: | Dane C. Andreeff |
|  | Title: | President and Chief Executive Officer |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Dane C. Andreeff and Jeffrey S. Mathiesen as his or her true and lawful attorneys-in-fact and agents with full power of substitution, severally, for him in any and all capacities, to sign the Registration Statement on Form S-8 of Helius Medical Technologies, Inc., and any or all amendments (including post-effective amendments thereto), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Dane C. Andreeff | President, Chief Executive Officer | July 10, 2025 |
| Dane C. Andreeff | (Principal Executive Officer) and Director |  |
| /s/ Jeffrey S. Mathiesen | Chief Financial Officer | July 10, 2025 |
| Jeffrey S. Mathiesen | (Principal Financial Officer and Principal Accounting Officer), <br> Treasurer, Secretary and Director |  |
| /s/ Paul Buckman | Director | July 10, 2025 |
| Paul Buckman |  |  |
| /s/ Blane Walter | Director | July 10, 2025 |
| Blane Walter |  |  |
| /s/ Sherrie Perkins | Director | July 10, 2025 |
| Sherrie Perkins |  |  |
| /s/ Edward M. Straw | Director | July 10, 2025 |
| Edward M. Straw |  |  |

---

## Exhibit 4.11

**Exhibit 4.11**

**AMENDMENT 2**

**TO**

**HELIUS MEDICAL TECHNOLOGIES, INC.**

**2022 Equity Incentive Plan**

**RECITALS**

A. Helius Medical Technologies, Inc., a Delaware corporation (the "***Company***") sponsors the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan, as amended (the "***Plan***").

B. The Plan is amended by this Amendment 2 (this "***Second Amendment***") in the following respects, effective from and after the date this Second Amendment is approved by the stockholders of Helius Medical Technologies, Inc., in accordance with Section 7(b) of the Plan. Following such effective date, any reference to the "Plan" shall mean the Plan, as amended by this Second Amendment. All capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Plan.

**AMENDMENT**

&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Section 2</u> of the Plan is hereby amended by adding the following at the end of subsection
2(a) of the Plan:

"In addition, on the 10th calendar day following the first closing of a registered offering of the Company's Common Stock that occurs after May 23, 2025, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will automatically increase to an amount equal to 20% of the Fully Diluted Shares as of the immediately preceding day; provided, however that the Board may act prior to the effective date of any such increase to provide that the increase will be a lesser number of shares of Common Stock."

&nbsp;&nbsp;&nbsp;&nbsp;2. Except as set forth in this amendment, the Plan shall be unaffected hereby and shall remain in full force
and effect.

## Exhibit 5.1

**Exhibit 5.1**

![](tm2520226d1_ex5-1img001.jpg)

July 10, 2025

Helius Medical Technologies, Inc.

642 Newtown Yardley Road, Suite 100

Newtown, Pennsylvania 18940

***Re: Registration Statement on Form S-8***

Ladies and Gentlemen:

We have acted as special counsel to Helius Medical Technologies, Inc., a Delaware corporation (the "<u>Company</u>"), in connection with the preparation and filing with the Securities and Exchange Commission (the "<u>Commission</u>") on or about July 10, 2025, of a Registration Statement on Form S-8 (the "<u>Registration Statement</u>") for the registration under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), of the issuance pursuant to awards under the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan (the "<u>Plan</u>") of a maximum of 240,000 shares of the Company's common stock, par value $0.001 per share (the "<u>Shares</u>").

In so acting, we have considered such matters of law and of fact, and relied upon, without independent investigation such documents, records, certificates and other information furnished to us as we have deemed appropriate as a basis for our opinions set forth below. In conducting such review, we have assumed, without independent investigation, the genuineness and authenticity of all signatures on original documents, the legal capacity of all natural persons or entities (other than the Company), the authenticity and completeness of all documents submitted to us as originals, the conformity to authentic and complete original documents of all documents submitted to us as copies, and the accuracy of all statements in certificates of public officials and officers of the Company that we reviewed.

The law covered by the opinions expressed in this opinion letter is limited to the General Corporation Law of the State of Delaware as currently in effect. We express no opinion as to any other laws.

This opinion speaks only at and as of its date and is based solely on the facts and circumstances known to us as of such date, and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

Based upon, subject to and limited by the foregoing, and subject to the assumptions stated and in reliance on statements of fact contained in the documents that we have examined, we are of the opinion that (i) when the Registration Statement has become effective under the Securities Act, (ii) when the individual grants or awards under the Plan are duly authorized by all necessary corporate action and duly granted or awarded and exercised in accordance with the requirements of law and the Plan (and the agreements and awards duly adopted thereunder and in accordance therewith) and (iii) when the Shares are issued and delivered in accordance with the terms of the Registration Statement, the Plan and the terms of such grants or awards, upon receipt by the Company of legal consideration in excess of par value for the Shares under the terms of such grants or awards, the Shares will be validly issued, fully paid and non-assessable.

We hereby consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement. In giving such consent, we do not admit that we are within the category of persons whose consent is required by Section 7 of the Securities Act or the rules and regulations promulgated thereunder by the Commission.

---

| |
|:---|
| Very truly yours, |
| /s/ Honigman LLP |
| Honigman LLP |

---

&nbsp;&nbsp;**Honigman LLP • 650 Trade Centre Way • Suite 200 • Kalamazoo, Michigan 49002-0402**<br> *Detroit ∙ Ann Arbor ∙ Bloomfield Hills ∙ Chicago ∙ Grand Rapids ∙ Kalamazoo ∙ Lansing ∙ Washington D.C.*<br>

## Exhibit 23.1

**Exhibit 23.1**

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statement on Form S-8 of Helius Medical Technologies, Inc. of our report dated March 25, 2025, relating to the consolidated financial statements of Helius Medical Technologies, Inc. in the Annual Report on Form 10-K for the year ended December 31, 2024. Our report contains an explanatory paragraph relating to the Company's ability to continue as a going concern.

/s/ Baker Tilly US, LLP

Minneapolis, Minnesota

July 10, 2025

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Table**

**FORM S-8**

**(Form Type)**

**Helius Medical Technologies, Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Newly Registered Securities**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Security<br> Type** | **Security Class Title** | **Fee<br> Calculation<br> or Carry<br> Forward<br> Rule** | **Maximum <br> Aggregate <br> Offering Price** | **Fee Rate** | **Amount of <br> Registration <br> Fee** |
| **Fees to be<br> Paid** |  |  |  |  |  |  |
|  | Equity | Class A Common Stock, par value $0.001 per share, to be issued under the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan | Other115800<sup>(2)</sup>$8.98<sup>(3)</sup> | $1039884.00<sup>(3)</sup> | 0.0001531 | $159.20 |
|  | Equity | Class A Common Stock, par value $0.001 per share, to be issued under the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan | Other124200<sup>(4)</sup>$9.76<sup>(5)</sup> | $1212192.00<sup>(3)</sup> | 0.0001531 | $185.59 |
| **Total Offering Amounts** |  |  |  | $2252076.00 |  | $344.79 |
| **Total Fees Previously Paid** |  |  |  |  |  | $-- |
| **Total Fee Offsets** |  |  |  |  |  | $-- |
| **Net Fee Due** |  |  |  |  |  | **$344.79** |

---

(1) Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended, (the "Securities Act"), this Registration Statement shall also cover any additional shares of Registrant's common stock that become issuable under the plan set forth herein by reason of any stock dividend, stock split, reclassification, recapitalization, spin-off or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Registrant's common stock, as applicable.

(2) Consists of shares reserved for future issuance under the 2022 Equity Incentive Plan ("2022 Plan").

(3) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act. The offering price per share and aggregate offering price are based on the average of the high and low prices of the Registrant's common stock as reported on the Nasdaq Capital Market on July 8, 2025.

(4) Consists of shares issuable upon exercise of stock options that have been granted under the 2022 Plan.

(5) Estimated solely for the purpose of calculating the registration fee pursuant to paragraph (h) of Rule 457 under the Securities Act. The proposed maximum offering price per share is based upon the exercise price for the shares of Class A common stock underlying outstanding stock options pursuant to Rule 457(h) under the Securities Act.